Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Russell who wrote (434)	12/4/1997 11:04:00 AM
From: LTK007	Read Replies (1) \| Respond to of 1580

Bruce,do you think it is this MK-869 news that is behind this mornings bull-rush on Merck?Up 5&1/2 pts in 1st hour of trading.Max P.S.I am a long time holder of this stock.(though it was not my purchase)

To: Bruce Russell who wrote (434)	12/4/1997 4:08:00 PM
From: Alan Wojtalik	Respond to of 1580

<maybe Merck can fill the patent expiration whole after all> I am counting on it. Not just with this MK-869, but with other drugs as well. A company like Merck is not just going to rest on its laurels. I'm sure they're well aware of when their major drugs go off patent, and are working on new drugs to fill the hole. That's why I've stuck with MRK despite all the panic talk about their drugs coming off patent in 2-3 years. I have a lot of faith in their R&D and management teams. They have plenty of time to develop replacements. I will gladly buy shares of MRK in the low 90's from the nay-sayers that would rather buy a Pfizer at a PE of 45 trailing, 38 projected just because it doesn't have drugs coming off patent as soon as MRK.